RESILIENCE, a San Diego-based provider of biopharma manufacturing technology, has launched with more than $800 million in total funding. The funding includes a $750 million Series B held in November 2020 and led by Arch Venture Partners and 8VC, with participation from GV, NEA, public mutual funds, some of the largest U.S.-based pharmaceutical companies, foundations, family offices, and pension funds, among others.
The startup has emerged from stealth to transform the way that drugs and therapies are manufactured in the U.S. The company will be actively investing in developing powerful new technologies to manufacture complex medicines that define the future of therapeutics, including cell and gene therapies, viral vectors, vaccines, and proteins. Through this, it endeavours to overcome one of the biggest challenges the biopharmaceutical industry is facing in pioneering innovative treatment modalities – manufacturing.
RESILIENCE will dramatically boost overall production capacity for these modalities, assuring that important medicines are accessible to all patients in need and will be shielding against supply chain disruption.
What RESILIENCE has to say
“We created RESILIENCE to reimagine biopharmaceutical manufacturing through an unprecedented investment in technology and a best-in-class team to execute our vision,” said Robert Nelsen, RESILIENCE founder, Chairman of the Board, and managing director at ARCH Venture Partners.
“COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model,” he also added.
“RESILIENCE has been designed to help society meet the challenges of tomorrow, whether that’s the next pandemic or high demand for a great new medicine. I am incredibly proud to lead a team of extraordinary professionals with deep and diverse talent to build a more resilient future,” said RESILIENCE Co-Founder and CEO Rahul Singhvi, Sc.D.
About RESILIENCE
RESILIENCE (National Resilience, Inc.) is one of a kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020 by Rahul Singhvi, Sandy Mahatme and Patrick Y. Yang, the company is creating a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at an acceptable scale.
About Arch Venture Partners
The firm invests primarily in companies co-founded by leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. Over 30 years, the company has backed disruptive science with as little as $50K and as much as $150M, per company. Headquartered in Chicago, it was founded by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus.
About 8VC
8VC is an investment firm that seeks to enable industry transformation. They believe that emerging platforms will replace the decades-old technology infrastructure behind many industries, which will hence promote greater innovation and global prosperity. Founded in 1969, 8VC is headquartered in San Francisco, California and founded by Alex Kolicich, Drew Oetting, Jake Medwell and Kimmy Scotti.
Read Next Story Here
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
[…] Read Next Story Here […]